Skip to content
2000
image of Intranasal Drug Delivery: Exploiting Nasal Anatomy for Enhanced Therapeutic Outcomes

Abstract

Nanotechnology has significantly improved drug delivery and targeting in central nervous system diseases and neurodegenerative diseases. Intranasal drug delivery has emerged as a promising approach for enhancing therapeutic outcomes by leveraging the unique anatomical and physiological characteristics of the nasal cavity. This route offers several advantages, including rapid absorption, bypassing the blood-brain barrier for central nervous system targeting, and improved patient compliance. The highly vascularized nasal mucosa facilitates efficient systemic drug absorption, making it an attractive option for both local and systemic treatments. This article explores the principles of intranasal drug delivery, the influence of nasal anatomy on drug bioavailability, and advancements in formulation strategies to optimize efficacy. Additionally, it addresses current challenges, including mucociliary clearance and enzymatic degradation, as well as innovative solutions designed to enhance drug stability and absorption. Understanding the interplay between nasal anatomy and drug delivery mechanisms can pave the way for novel therapeutic interventions and enhance the effectiveness of intranasal medications in various clinical applications. It also highlights challenges in the nasal delivery of therapeutics.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128392902250916114510
2025-10-06
2026-02-28

  • From This Site

    /content/journals/cpd/10.2174/0113816128392902250916114510
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Djupesland P.G. Doekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia 2010 30 8 933 942 10.1177/0333102409359314 20656704
    [Google Scholar]
  2. Shirindza N. Bronkhorst E. Management of allergy and sinusitis. S. Afr. Pharm. J. 2024 91 3 13 18 10.36303/SAPJ.0491
    [Google Scholar]
  3. Katare P. Pawar Medhe T. Nadkarni A. Nasal drug delivery system and devices: An overview on health effects. J. Chem. Health Saf. 2024 31 2 127 143 10.1021/acs.chas.3c00069
    [Google Scholar]
  4. Zhang X. Zhao L. Wu J. Current advances in vehicles for brain gene delivery. Curr. Gene Ther. 2012 12 5 423 436 10.2174/156652312802762590 22827222
    [Google Scholar]
  5. Rutvik K. Meshva P. Dinal P. Mansi D. The nasal route, advanced drug delivery systems and evaluation: A review. Egypt. J. Chest Dis. Tuberc. 2023 72 4 471 477 10.4103/ecdt.ecdt_122_22
    [Google Scholar]
  6. Losada-Barreiro S. Celik S. Sezgin-Bayindir Z. Bravo-Fernández S. Bravo-Díaz C. Carrier systems for advanced drug delivery: Improving drug solubility/bioavailability and administration routes. Pharmaceutics 2024 16 7 852 10.3390/pharmaceutics16070852 39065549
    [Google Scholar]
  7. Khosrow Tayebati S. Ejike Nwankwo I. Amenta F. Intranasal drug delivery to the central nervous system: Present status and future outlook. Curr. Pharm. Des. 2013 19 3 510 526 10.2174/138161213804143662 23116337
    [Google Scholar]
  8. Sasaki H. Ishikawa H. Kojima K. Intranasal immunization with a non-adjuvanted adhesive protein descended from Pasteurella pneumotropica and its preventive efficacy against opportunistic infection in mice. Vaccine 2013 31 48 5729 5735 10.1016/j.vaccine.2013.09.033 24091313
    [Google Scholar]
  9. Watanabe K. Matsubara A. Kawano M. Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. Vaccine 2014 32 15 1727 1735 10.1016/j.vaccine.2013.11.108 24486310
    [Google Scholar]
  10. Misra A. Kher G. Drug delivery systems from nose to brain. Curr. Pharm. Biotechnol. 2012 13 12 2355 2379 10.2174/138920112803341752 23016642
    [Google Scholar]
  11. Jeong S.H. Jang J.H. Lee Y.B. Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors. J. Pharm. Investig. 2023 53 1 119 152 10.1007/s40005‑022‑00589‑5 35910081
    [Google Scholar]
  12. Proetz A.W. Displacement irrigation of nasal sinuses: A new procedure in diagnosis and conservative treatment. Arch. Otolaryngol. Head Neck Surg. 1926 4 1 1 13 10.1001/archotol.1926.00590010009001
    [Google Scholar]
  13. Foulds W.S. Gkeaves D.P. Herxheimer H. Kingdom L.G. Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma. Lancet 1955 265 6857 234 235 10.1016/S0140‑6736(55)90164‑1 13234340
    [Google Scholar]
  14. Godfrey M.P. Maunsell K. Pearson R.S.B. Prednisolone snuff in hayfever; a controlled trial. Lancet 1957 269 6972 767 769 10.1016/S0140‑6736(57)91029‑2 13417591
    [Google Scholar]
  15. Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. BMJ 1973 4 5890 464 466 10.1136/bmj.4.5890.464 4586044
    [Google Scholar]
  16. Norman P.S. Winkenwerder W.L. Agbayani B.F. Migeon C.J. Adrenal function during the use of dexamethasone aerosols in the treatment of ragweed hay fever. J. Allergy 1967 40 1 57 61 10.1016/0021‑8707(67)90060‑3 5230040
    [Google Scholar]
  17. Dalton M. Bromham D.R. Ambrose C.L. Osborne J. Dalton K.D. Nasal absorption of progesterone in women. BJOG 1987 94 1 84 88 10.1111/j.1471‑0528.1987.tb02258.x 3814560
    [Google Scholar]
  18. Shrewsbury S.B. The pharmacokinetics of drugs delivered to the upper nasal space. Pharmaceut. Med. 2023 37 6 451 461 10.1007/s40290‑023‑00495‑7 37537422
    [Google Scholar]
  19. Shrewsbury S.B. The upper nasal space: Option for systemic drug delivery, mucosal vaccines and “nose-to-brain”. Pharmaceutics 2023 15 6 1720 10.3390/pharmaceutics15061720 37376168
    [Google Scholar]
  20. Feng C. Zhang C. Shao X. Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of -amyloid and ibotenic acid into the bilateral hippocampus. Int. J. Pharm. 2012 423 2 226 234 10.1016/j.ijpharm.2011.12.008 22193058
    [Google Scholar]
  21. Sanap S.N. Bisen A.C. Kedar A. Agrawal S. Bhatta R.S. Recent update on pharmacokinetics and drug metabolism in cns-based drug discovery. Curr. Pharm. Des. 2023 29 20 1602 1616 10.2174/1381612829666230707121415 37424342
    [Google Scholar]
  22. Chung S. Peters J.M. Detyniecki K. Tatum W. Rabinowicz A.L. Carrazana E. The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy Behav. Rep. 2023 21 100581 10.1016/j.ebr.2022.100581 36636458
    [Google Scholar]
  23. Kehagia E. Papakyriakopoulou P. Valsami G. Advances in intranasal vaccine delivery: A promising non-invasive route of immunization. Vaccine 2023 41 24 3589 3603 10.1016/j.vaccine.2023.05.011 37179163
    [Google Scholar]
  24. Nakahashi-Ouchida R. Fujihashi K. Kurashima Y. Yuki Y. Kiyono H. Nasal vaccines: Solutions for respiratory infectious diseases. Trends Mol. Med. 2023 29 2 124 140 10.1016/j.molmed.2022.10.009 36435633
    [Google Scholar]
  25. Ahmed S. Sileno A.P. deMeireles J.C. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm. Res. 2000 17 8 974 977 10.1023/A:1007551927177 11028944
    [Google Scholar]
  26. Michelotti B. Mackay D. Nasal reconstruction. Clin. Anat. 2012 25 1 86 98 10.1002/ca.21295 22038869
    [Google Scholar]
  27. Mygind N. Dahl R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv. Drug Deliv. Rev. 1998 29 1-2 3 12 10.1016/S0169‑409X(97)00058‑6 10837577
    [Google Scholar]
  28. Kelly J.T. Prasad A.K. Wexler A.S. Detailed flow patterns in the nasal cavity. J. Appl. Physiol. 2000 89 1 323 337 10.1152/jappl.2000.89.1.323 10904068
    [Google Scholar]
  29. Proctor D.F. Lundqvist G. Clearance of inhaled particles from the human nose. Arch. Intern. Med. 1973 131 1 132 139 10.1001/archinte.1973.00320070128014 4682059
    [Google Scholar]
  30. Gross E. Mellick P.W. Kari F.W. Miller F.J. Morgan K.T. Histopathology and cell replication responses in the respiratory tract of rats and mice exposed by inhalation to glutaraldehyde for up to 13 weeks. Fundam. Appl. Toxicol. 1994 23 3 348 362 10.1006/faat.1994.1115 7835535
    [Google Scholar]
  31. Morrison E.E. Costanzo R.M. Morphology of the human olfactory epithelium. J. Comp. Neurol. 1990 297 1 1 13 10.1002/cne.902970102 2376627
    [Google Scholar]
  32. Illum L. Nasal delivery. The use of animal models to predict performance in man. J. Drug Target. 1996 3 6 427 442 10.3109/10611869609015963 8863136
    [Google Scholar]
  33. Reznik G.K. Comparative anatomy, physiology, and function of the upper respiratory tract. Environ. Health Perspect. 1990 85 171 176 2384061
    [Google Scholar]
  34. Geurkink N. Nasal anatomy, physiology, and function. J. Allergy Clin. Immunol. 1983 72 2 123 128 10.1016/0091‑6749(83)90518‑3 6350406
    [Google Scholar]
  35. Duchateau G.S.M.J.E. Merkus F.W.H.M. Zuidema J. Graamans K. Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers. Laryngoscope 1985 95 7 854 859 10.1288/00005537‑198507000‑00022 4010429
    [Google Scholar]
  36. Holmberg K. Pipkorn U. Influence of topical beclomethasone dipropionate suspension on human nasal mucociliary activity. Eur. J. Clin. Pharmacol. 1986 30 5 625 627 10.1007/BF00542425 3758151
    [Google Scholar]
  37. Carson J.L. Collier A.M. Hu S. Smith C.A. Stewart P. The appearance of compound cilia in the nasal mucosa of normal human subjects following acute, in Vivo exposure to sulfur dioxide. Environ. Res. 1987 42 1 155 165 10.1016/S0013‑9351(87)80017‑8 3803334
    [Google Scholar]
  38. Marttin E. Verhoef J.C. Cullander C. Romeijn S.G. Nagelkerke J.F. Merkus F.W.H.M. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: Effects of absorption enhancers. Pharm. Res. 1997 14 5 631 637 10.1023/A:1012109329631 9165535
    [Google Scholar]
  39. Morrison E.E. Costanzo R.M. Morphology of olfactory epithelium in humans and other vertebrates. Microsc. Res. Tech. 1992 23 1 49 61 10.1002/jemt.1070230105 1392071
    [Google Scholar]
  40. Uraih L.C. Maronpot R.R. Normal histology of the nasal cavity and application of special techniques. Environ. Health Perspect. 1990 85 187 208 2200662
    [Google Scholar]
  41. Kaliner M. Marom Z. Patow C. Shelhamer J. Human respiratory mucus. J. Allergy Clin. Immunol. 1984 73 3 318 323 10.1016/0091‑6749(84)90403‑2 6366031
    [Google Scholar]
  42. Marttin E. Schipper N.G.M. Verhoef J.C. Merkus F.W.H.M. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. 1998 29 1-2 13 38 10.1016/S0169‑409X(97)00059‑8 10837578
    [Google Scholar]
  43. Sanderson M.J. Sleigh M.A. Ciliary activity of cultured rabbit tracheal epithelium: Beat pattern and metachrony. J. Cell Sci. 1981 47 1 331 347 10.1242/jcs.47.1.331 7263784
    [Google Scholar]
  44. Washington N. Steele R.J.C. Jackson S.J. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int. J. Pharm. 2000 198 2 139 146 10.1016/S0378‑5173(99)00442‑1 10767563
    [Google Scholar]
  45. Fabricant N.D. Significance of the PH of nasal secretions in situ. Arch. Otolaryngol. Head Neck Surg. 1941 34 1 150 163 10.1001/archotol.1941.00660040160016
    [Google Scholar]
  46. Baroody F.M. Nasal and paranasal sinus anatomy and physiology. Clin. Allergy Immunol. 2007 19 1 21 17153004
    [Google Scholar]
  47. Bogdanffy M. Randall H.W. Morgan K.T. Biochemical quantitation and histochemical localization of carboxylesterase in the nasal passages of the fischer-344 rat and B6C3F1 mouse. Toxicol. Appl. Pharmacol. 1987 88 2 183 194 10.1016/0041‑008X(87)90004‑4 3564037
    [Google Scholar]
  48. Stratford R.E. Lee V.H.L. Aminopeptidase activity in homogenates of various absorptive mucosae m the albino rabbit: Implications in peptide delivery. Int. J. Pharm. 1986 30 1 73 82 10.1016/0378‑5173(86)90137‑7
    [Google Scholar]
  49. Hadley W.M. Dahl A.R. Cytochrome P-450 dependent monooxygenase activity in rat nasal epithelial membranes. Toxicol. Lett. 1982 10 4 417 422 10.1016/0378‑4274(82)90240‑5 7089996
    [Google Scholar]
  50. Brittebo E.B. N-Demethylation of aminopyrine by the nasal mucosa in mice and rats. Acta Pharmacol. Toxicol. 1982 51 3 227 232 10.1111/j.1600‑0773.1982.tb01018.x 6814187
    [Google Scholar]
  51. Longo V. Citti L. Gervasi P. Biotransformation enzymes in nasal mucosa and liver of Sprague-Dawley rats. Toxicol. Lett. 1988 44 3 289 297 10.1016/0378‑4274(88)90168‑3 3217944
    [Google Scholar]
  52. Drettner B. Aust R. Plethysmographic studies of the blood flow in the mucosa of the human maxillary sinus. Acta Otolaryngol. 1974 78 1-6 259 263 10.3109/00016487409126353 4432750
    [Google Scholar]
  53. Chien Y.W. Chang S.F. Intranasal drug delivery for systemic medications. Crit. Rev. Ther. Drug Carrier Syst. 1987 4 2 67 194 3319200
    [Google Scholar]
  54. Harvey R.J. Roland L.T. Schlosser R.J. Pfaar O. Chief complaint: Nasal congestion. J. Allergy Clin. Immunol. Pract. 2024 12 6 1462 1471 10.1016/j.jaip.2024.04.028 38677589
    [Google Scholar]
  55. Ottaviano G. Physiology: Nasal airflow contemporary rhinology: Science and practice. Cham Springer International Publishing 2023 33 42 10.1007/978‑3‑031‑28690‑2_3
    [Google Scholar]
  56. Seifelnasr A. Si X. Xi J. Assessing nasal epithelial dynamics: Impact of the natural nasal cycle on intranasal spray deposition. Pharmaceuticals 2024 17 1 73 10.3390/ph17010073 38256906
    [Google Scholar]
  57. Hafner A. Szabó-Révész P. Nose Practical Pharmaceutics. Cham Springer International Publishing 2023 345 366 10.1007/978‑3‑031‑20298‑8_16
    [Google Scholar]
  58. Pires A. Fortuna A. Alves G. Falcão A. Intranasal drug delivery: How, why and what for? J. Pharm. Pharm. Sci. 2009 12 3 288 311 10.18433/J3NC79 20067706
    [Google Scholar]
  59. Zheng S. Guo Y. Yan F. Yan F. Qi R. Shen J. Chances and challenges in intranasal administration delivery for brain disease treatment. Clin. Transl. Discov. 2023 3 6 253 10.1002/ctd2.253
    [Google Scholar]
  60. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000 11 1 1 18 10.1016/S0928‑0987(00)00087‑7 10913748
    [Google Scholar]
  61. Bahadur S. Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin. Drug Deliv. 2012 9 1 19 31 10.1517/17425247.2012.636801 22171740
    [Google Scholar]
  62. Bertram U. Bodmeier R. Effect of polymer molecular weight and of polymer blends on the properties of rapidly gelling nasal inserts. Drug Dev. Ind. Pharm. 2012 38 6 659 669 10.3109/03639045.2011.598536 22537309
    [Google Scholar]
  63. Illum L. Nasal drug delivery—possibilities, problems and solutions. J. Control. Release 2003 87 1-3 187 198 10.1016/S0168‑3659(02)00363‑2 12618035
    [Google Scholar]
  64. Kumar M. Kakkar V. Mishra A.K. Chuttani K. Kaur I.P. Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. Int. J. Pharm. 2014 461 1-2 223 233 24286922
    [Google Scholar]
  65. Zhang X. Zhang M. Sui H. Prevalence and risk factors of allergic rhinitis among Chinese adults: A nationwide representative cross-sectional study. World Allergy Organ. J. 2023 16 3 100744 10.1016/j.waojou.2023.100744 37008533
    [Google Scholar]
  66. Wise S.K. Damask C. Roland L.T. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023. Int. Forum Allergy Rhinol. 2023 13 4 293 859 10.1002/alr.23090 36878860
    [Google Scholar]
  67. Alobid I. Benitez P. Valero A. Munoz R. Langdon C. Mullol J. Oral and intranasal steroid treatments improve nasal patency and paradoxically increase nasal nitric oxide in patients with severe nasal polyposis. Rhinology 2012 50 2 171 177 10.4193/Rhin10.140
    [Google Scholar]
  68. Bertazzoni G. Conti C. Testa G. Pipolo G.C. Mattavelli D. Piazza C. High volume nasal irrigations with steroids for chronic rhinosinusitis and allergic rhinitis. Eur. Arch. Otorhinolaryngol. 2025 282 1 47 62 10.1007/s00405‑024‑08901‑9
    [Google Scholar]
  69. Skröder C. Hellkvist L. Dahl Å. Limited beneficial effects of systemic steroids when added to standard of care treatment of seasonal allergic rhinitis. Sci. Rep. 2023 13 1 19649 10.1038/s41598‑023‑46869‑4 37950032
    [Google Scholar]
  70. Calvo-Henriquez C. Viera-Artiles J. Rodriguez-Iglesias M. The role of corticosteroid nasal irrigations in the management of chronic rhinosinusitis: A state-of-the-art systematic review. J. Clin. Med. 2023 12 10 3605 10.3390/jcm12103605 37240711
    [Google Scholar]
  71. Aukema A. Mulder P. Fokkens W. Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. J. Allergy Clin. Immunol. 2005 115 5 1017 1023 10.1016/j.jaci.2004.12.1144 15867860
    [Google Scholar]
  72. Benninger M.S. Ahmad N. Marple B.F. The safety of intranasal steroids. Otolaryngol. Head Neck Surg. 2003 129 6 739 750 10.1016/j.otohns.2003.10.001 14663444
    [Google Scholar]
  73. Bitter C. Suter-Zimmermann K. Surber C. Nasal drug delivery in humans. Curr. Probl. Dermatol. 2011 40 20 35 10.1159/000321044
    [Google Scholar]
  74. Kantar A. Targeting the nasal cavity in rhinitis and sinusitis. Int. J. Immunopathol. Pharmacol. 2010 23 1 Suppl. 67 69 10.1177/03946320100230S117 20152085
    [Google Scholar]
  75. See K.C. Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review. World J. Diabetes 2023 14 8 1202 1211 10.4239/wjd.v14.i8.1202 37664474
    [Google Scholar]
  76. Yadav H.K.S. Lim-Dy A. Pathak Y.V. An overview of the anatomy and physiology of nasal passage from drug delivery point of view nasal drug delivery. Cham Springer International Publishing 2023 1 13
    [Google Scholar]
  77. Chen Y. Zhang C. Huang Y. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. Adv. Drug Deliv. Rev. 2024 207 115196 10.1016/j.addr.2024.115196 38336090
    [Google Scholar]
  78. Davis S.S. Eccles R. Nasal congestion: Mechanisms, measurement and medications. Core information for the clinician. Clin. Otolaryngol. Allied Sci. 2004 29 6 659 666 10.1111/j.1365‑2273.2004.00885.x 15533155
    [Google Scholar]
  79. Beule A.G. Weber R.K. Function of the turbinates: Nasal cycle nasal physiology and pathophysiology of nasal disorders. Cham Springer International Publishing 2023 245 253 10.1007/978‑3‑031‑12386‑3_21
    [Google Scholar]
  80. Shusterman D. Trigeminal function in sino-nasal health and disease. Biomedicines 2023 11 7 1778 10.3390/biomedicines11071778 37509418
    [Google Scholar]
  81. Gwaltney J.M. Buier R.M. Rogers J.L. The influence of signal variation, bias, noise and effect size on statistical significance in treatment studies of the common cold. Antiviral Res. 1996 29 2-3 287 295 10.1016/0166‑3542(95)00935‑3 8739607
    [Google Scholar]
  82. Jankowski R. Favier V. Saroul N. Critical review of diagnosis in rhinology and its therapeutical implications. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2023 140 6 271 278 10.1016/j.anorl.2023.10.006 37838600
    [Google Scholar]
  83. Anne J. Sreedharan S. Dosemane D. Shenoy V. Kamath P.M. Zubair S.M. Predictors of surgical outcomes after functional endoscopic sinus surgery in chronic rhinosinusitis. Indian J. Otolaryngol. Head Neck Surg. 2022 74 S2 835 841 10.1007/s12070‑020‑01855‑4 36452725
    [Google Scholar]
  84. Larsen P.L. Tingsgaard P.K. Harcourt J. Sofsrud G. Tos M. Nasal polyps and their relation to polyps/hypertrophic polypoid mucosa in the paranasal sinuses: A macro-, endo-, and microscopic study of autopsy materials. Am. J. Rhinol. 1998 12 1 45 52 10.2500/105065898782103052 9513659
    [Google Scholar]
  85. Mygind N. 3. Advances in the medical treatment of nasal polyps. Allergy 1999 54 s53 12 16 10.1111/j.1398‑9995.1999.tb05032.x 10442545
    [Google Scholar]
  86. Davraj K. Yadav M. Chappity P. Sharma P. Grover M. Sharma S. Nasal physiology and sinusitis essentials of rhinology. Singapore Springer Singapore 2021 49 101 10.1007/978‑981‑33‑6284‑0_3
    [Google Scholar]
  87. Hallworth G. Padfield J. A comparison of the regional depesition in a model nose of a drug discharged from metered serosel and metered-pump nasal delivery systems. J. Allergy Clin. Immunol. 1986 77 2 348 353 10.1016/S0091‑6749(86)80116‑6 3944385
    [Google Scholar]
  88. Morén F. Björnek K. Klint T. Wagner Z.G. A comparative distribution study of two procedures for administration of nose drops. Acta Otolaryngol. 1988 106 3-4 286 290 10.3109/00016488809106438 3176972
    [Google Scholar]
  89. Benninger M.S. Hadley J.A. Osguthorpe J.D. Techniques of intranasal steroid use. Otolaryngol. Head Neck Surg. 2004 130 1 5 24 10.1016/j.otohns.2003.10.007 14726906
    [Google Scholar]
  90. Homer J.J. Raine C.H. An endoscopic photographic comparison of nasal drug delivery by aqueous spray. Clin. Otolaryngol. Allied Sci. 1998 23 6 560 563 10.1046/j.1365‑2273.1998.2360560.x 9884813
    [Google Scholar]
  91. Ugwoke M.I. Verbeke N. Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001 53 1 3 21 10.1211/0022357011775145 11206189
    [Google Scholar]
  92. Bijani C. Arnarez C. Brasselet S. Stability and structure of protein-lipoamino acid colloidal particles: Toward nasal delivery of pharmaceutically active proteins. Langmuir 2012 28 13 5783 5794 10.1021/la300222v 22394194
    [Google Scholar]
  93. Malerba F. Paoletti F. Capsoni S. Cattaneo A. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin. Drug Deliv. 2011 8 10 1277 1296 10.1517/17425247.2011.588204 21619468
    [Google Scholar]
  94. Chung S.W. Hil-lal T.A. Byun Y. Strategies for non-invasive delivery of biologics. J. Drug Target. 2012 20 6 481 501 10.3109/1061186X.2012.693499 22632037
    [Google Scholar]
  95. Jones N.S. Quraishi S. Mason J.D.T. The nasal delivery of systemic drugs. Int. J. Clin. Pract. 1997 51 5 308 311 10.1111/j.1742‑1241.1997.tb11466.x 9489091
    [Google Scholar]
  96. Arora P. Sharma S. Garg S. Permeability issues in nasal drug delivery. Drug Discov. Today 2002 7 18 967 975 10.1016/S1359‑6446(02)02452‑2 12546871
    [Google Scholar]
  97. Qin L. Cui Z. Wu Y. Challenges and strategies to enhance the systemic absorption of inhaled peptides and proteins. Pharm. Res. 2023 40 5 1037 1055 10.1007/s11095‑022‑03435‑3 36385216
    [Google Scholar]
  98. Gandhi S. Shastri D.H. Shah J. Nair A.B. Jacob S. Nasal delivery to the brain: Harnessing nanoparticles for effective drug transport. Pharmaceutics 2024 16 4 481 10.3390/pharmaceutics16040481 38675142
    [Google Scholar]
  99. Abdelbary G.A. Tadros M.I. Brain targeting of olanzapine via intranasal delivery of core–shell difunctional block copolymer mixed nanomicellar carriers: In vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies. Int. J. Pharm. 2013 452 1-2 300 310 10.1016/j.ijpharm.2013.04.084 23684658
    [Google Scholar]
  100. Akpan N. Serrano-Saiz E. Zacharia B.E. Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J. Neurosci. 2011 31 24 8894 8904 10.1523/JNEUROSCI.0698‑11.2011 21677173
    [Google Scholar]
  101. Al-Ghananeem A.M. Saeed H. Florence R. Yokel R.A. Malkawi A.H. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. J. Drug Target. 2010 18 5 381 388 10.3109/10611860903483396 20001275
    [Google Scholar]
  102. Allhenn D. Shetab Boushehri M.A. Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int. J. Pharm. 2012 436 1-2 299 310 10.1016/j.ijpharm.2012.06.025 22721856
    [Google Scholar]
  103. Pardeshi C.V. Belgamwar V.S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: An excellent platform for brain targeting. Expert Opin. Drug Deliv. 2013 10 7 957 972 10.1517/17425247.2013.790887 23586809
    [Google Scholar]
  104. Chapman C.D. Frey W.H. Craft S. Intranasal treatment of central nervous system dysfunction in humans. Pharm. Res. 2013 30 10 2475 2484 10.1007/s11095‑012‑0915‑1 23135822
    [Google Scholar]
  105. Craft S. Baker L.D. Montine T.J. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch. Neurol. 2012 69 1 29 38 10.1001/archneurol.2011.233 21911655
    [Google Scholar]
  106. Tambe P. Undale V. Sanap A. Bhonde R. Mante N. The prospective role of mesenchymal stem cells in Parkinson’s disease. Parkinsonism Relat. Disord. 2024 127 107087 10.1016/j.parkreldis.2024.107087 39142905
    [Google Scholar]
  107. Niazi S.K. Mariam Z. Magoola M. Engineered antibodies to improve efficacy against neurodegenerative disorders. Int. J. Mol. Sci. 2024 25 12 6683 10.3390/ijms25126683 38928395
    [Google Scholar]
  108. Caban S. Capan Y. Couvreur P. Dalkara T. Preparation and characterization of biocompatible chitosan nanoparticles for targeted brain delivery of peptides. In: Skaper S, Ed Neurotrophic Factors. Humana Press 2012 846 10.1007/978‑1‑61779‑536‑7_27
    [Google Scholar]
  109. Veronesi M.C. Kubek D.J. Kubek M.J. Intranasal delivery of neuropeptides. Methods Mol. Biol. 2011 789 303 312 10.1007/978‑1‑61779‑310‑3_20
    [Google Scholar]
  110. Ansari M.M. Nanotechnology approach for nose-to-brain drug delivery. In: Rath SK, Dwibedi V, Husen A, Eds. Nanomaterials for Drug Delivery and Neurological Diseases Management. Singapore Springer 2024 10.1007/978‑981‑97‑0308‑1_9
    [Google Scholar]
  111. Jain N. Akhter S. Jain G. Khan Z. Khar R. Ahmad F. Antiepileptic intranasal Amiloride loaded mucoadhesive nanoemulsion: Development and safety assessment. J. Biomed. Nanotechnol. 2011 7 1 142 143 10.1166/jbn.2011.1240 21485842
    [Google Scholar]
  112. Alex A.T. Joseph A. Shavi G. Rao J.V. Udupa N. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv. 2016 23 7 2144 2153 10.3109/10717544.2014.948643 25544603
    [Google Scholar]
  113. Kulkarni P.V. Roney C.A. Antich P.P. Bonte F.J. Raghu A.V. Aminabhavi T.M. Quinoline n butylcyanoacrylatebased nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010 2 1 35 47 10.1002/wnan.59 20049829
    [Google Scholar]
  114. Bhavna M.S. Md S. Ali M. Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. Int. J. Biol. Macromol. 2014 67 418 425 10.1016/j.ijbiomac.2014.03.022 24705169
    [Google Scholar]
  115. Bragagni M. Mennini N. Ghelardini C. Mura P. Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. J. Pharm. Pharm. Sci. 2012 15 1 184 196 10.18433/J3230M 22365096
    [Google Scholar]
  116. Wu H. Li J. Zhang Q. A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and pharmacodynamic study on amyloid-β25–35-treated rats following intranasal administration. Eur. J. Pharm. Biopharm. 2012 80 2 368 378 10.1016/j.ejpb.2011.10.012 22061263
    [Google Scholar]
  117. Cho H.J. Balakrishnan P. Shim W.S. Chung S.J. Shim C.K. Kim D.D. Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron–cyclodextrin complex and carboxymethylcellulose for intranasal delivery. Int. J. Pharm. 2010 400 1-2 59 65 10.1016/j.ijpharm.2010.08.030 20801202
    [Google Scholar]
  118. Hanson L.R. Fine J.M. Hoekman J.D. Intranasal delivery of growth differentiation factor 5 to the central nervous system. Drug Deliv. 2012 19 3 149 154 10.3109/10717544.2012.657720 22353012
    [Google Scholar]
  119. Hu K-L. Mei N. Feng L. Jiang X-G. Hydrophilic nasal gel of lidocaine hydrochloride. 2nd communication: Improved bioavailability and brain delivery in rats with low ciliotoxicity. Arzneimittelforschung 2009 59 12 635 640 20108649
    [Google Scholar]
  120. Jug M. Beirevi-Laan M. Development of a cyclodextrin-based nasal delivery system for lorazepam. Drug Dev. Ind. Pharm. 2008 34 8 817 826 10.1080/03639040801926063 18622800
    [Google Scholar]
  121. Jayachandra Babu R. Dayal P.P. Pawar K. Singh M. Nose-to-brain transport of melatonin from polymer gel suspensions: A microdialysis study in rats. J. Drug Target. 2011 19 9 731 740 10.3109/1061186X.2011.558090 21428693
    [Google Scholar]
  122. Gaillard P.J. Appeldoorn C.C.M. Rip J. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J. Control. Release 2012 164 3 364 369 10.1016/j.jconrel.2012.06.022 22732475
    [Google Scholar]
  123. Ruan Y. Yao L. Zhang B. Zhang S. Guo J. Antinociceptive properties of nasal delivery of Neurotoxin-loaded nanoparticles coated with polysorbate-80. Peptides 2011 32 7 1526 1529 10.1016/j.peptides.2011.05.002 21600257
    [Google Scholar]
  124. Salama H.A. Mahmoud A.A. Kamel A.O. Abdel Hady M. Awad G.A.S. Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J. Liposome Res. 2012 22 4 336 345 10.3109/08982104.2012.700460 22881283
    [Google Scholar]
  125. Seju U. Kumar A. Sawant K.K. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater. 2011 7 12 4169 4176 10.1016/j.actbio.2011.07.025 21839863
    [Google Scholar]
  126. Kumar M. Misra A. Mishra A.K. Mishra P. Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J. Drug Target. 2008 16 10 806 814 10.1080/10611860802476504 18988064
    [Google Scholar]
  127. Joshi A.S. Patel H.S. Belgamwar V.S. Agrawal A. Tekade A.R. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: Development, optimization and evaluation. J. Mater. Sci. Mater. Med. 2012 23 9 2163 2175 10.1007/s10856‑012‑4702‑7 22802103
    [Google Scholar]
  128. Kumar M. Misra A. Babbar A.K. Mishra A.K. Mishra P. Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 2008 358 1-2 285 291 10.1016/j.ijpharm.2008.03.029 18455333
    [Google Scholar]
  129. Patel S. Chavhan S. Soni H. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J. Drug Target. 2011 19 6 468 474 10.3109/1061186X.2010.523787 20958095
    [Google Scholar]
  130. Fazil M. Md S. Haque S. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 2012 47 1 6 15 10.1016/j.ejps.2012.04.013 22561106
    [Google Scholar]
  131. Jafarieh O. Md S. Ali M. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 2015 41 10 1674 1681 10.3109/03639045.2014.991400 25496439
    [Google Scholar]
  132. Jain R. Nabar S. Dandekar P. Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine 2010 5 4 575 587 10.2217/nnm.10.28 20528453
    [Google Scholar]
  133. Luppi B. Bigucci F. Corace G. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur. J. Pharm. Sci. 2011 44 4 559 565 10.1016/j.ejps.2011.10.002 22009109
    [Google Scholar]
  134. Belgamwar V.S. Patel H.S. Joshi A.S. Agrawal A. Surana S.J. Tekade A.R. Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Deliv. 2011 18 5 353 360 10.3109/10717544.2011.557787 21351825
    [Google Scholar]
  135. Wen Z. Yan Z. He R. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration. Drug Deliv. 2011 18 8 555 561 10.3109/10717544.2011.596583 21812752
    [Google Scholar]
  136. Eskandari S. Varshosaz J. Minaiyan M. Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int. J. Nanomedicine 2011 6 363 371 21499426
    [Google Scholar]
  137. Kao Y.Y. Cheng T.J. Yang D.M. Wang C.T. Chiung Y.M. Liu P.S. Demonstration of an olfactory bulb-brain translocation pathway for ZnO nanoparticles in rodent cells in vitro and in vivo. J. Mol. Neurosci. 2012 48 2 464 471 10.1007/s12031‑012‑9756‑y 22528453
    [Google Scholar]
  138. Bahadur S. Pathak K. Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: Preformulation and pharmacodynamic evaluation. Curr. Drug Deliv. 2012 9 6 596 607 10.2174/156720112803529792 22788695
    [Google Scholar]
  139. Jain R. Nabar S. Dandekar P. Patravale V. Micellar nanocarriers: Potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm. Res. 2010 27 4 655 664 10.1007/s11095‑009‑0041‑x 20151180
    [Google Scholar]
  140. Ghosh A. Majie A. Karmakar V. In-depth mechanism, challenges, and opportunities of delivering therapeutics in brain using intranasal route. AAPS PharmSciTech 2024 25 5 96 10.1208/s12249‑024‑02810‑0 38710855
    [Google Scholar]
  141. Suwabe S. Tagami T. Ogawa K. Ozeki T. Improved drug transfer into brain tissue via the “nose-to-brain” approach using suspension or powder formulations based on the amorphous solid dispersion technique. Eur. J. Pharm. Biopharm. 2023 185 137 147 10.1016/j.ejpb.2023.02.012 36842719
    [Google Scholar]
  142. Lee D. Shen A.M. Garbuzenko O.B. Minko T. Liposomal formulations of anti-alzheimer drugs and sirna for nose-to-brain delivery: Design, safety and efficacy in vitro. AAPS J. 2024 26 5 99 10.1208/s12248‑024‑00967‑x 39231845
    [Google Scholar]
  143. Patharapankal E.J. Ajiboye A.L. Mattern C. Trivedi V. Nose-to-brain (N2B) delivery: An alternative route for the delivery of biologics in the management and treatment of central nervous system disorders. Pharmaceutics 2023 16 1 66 10.3390/pharmaceutics16010066 38258077
    [Google Scholar]
  144. Du L. Chen L. Liu F. Wang W. Huang H. Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies. Int. Rev. Neurobiol. 2023 171 255 297 10.1016/bs.irn.2023.05.014
    [Google Scholar]
  145. Löwhagen P. Johansson B.B. Nordborg C. The nasal route of cerebrospinal fluid drainage in man. A light–microscope study. Neuropathol. Appl. Neurobiol. 1994 20 6 543 550 10.1111/j.1365‑2990.1994.tb01008.x 7898616
    [Google Scholar]
  146. Mathison S. Nagilla R. Kompella U.B. Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction? J. Drug Target. 1998 5 6 415 441 10.3109/10611869808997870 9783675
    [Google Scholar]
  147. Xiang Z. Ertl H.C. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine 1999 17 15-16 2003 2008 10.1016/S0264‑410X(98)00449‑6 10217600
    [Google Scholar]
  148. Bian J. Yuan Z. Chen X. Gao Y. Xu C. Shi J. Preparation of surface multiple-coated polylactide acid drug-loaded nanoparticles for intranasal delivery and evaluation on its brain-targeting efficiency. Drug Deliv. 2016 23 1 269 276 10.3109/10717544.2014.910566 24845477
    [Google Scholar]
  149. Ang V.T.Y. Jenkins J.S. Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog. J. Endocrinol. 1982 93 3 319 325 10.1677/joe.0.0930319 7086325
    [Google Scholar]
  150. Chou K.J. Donovan M.D. The distribution of local anesthetics into the CSF following intranasal administration. Int. J. Pharm. 1998 168 2 137 145 10.1016/S0378‑5173(98)00061‑1
    [Google Scholar]
  151. Bshara H. Osman R. Mansour S. El-Shamy A.E.H.A. Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats. Carbohydr. Polym. 2014 99 297 305 10.1016/j.carbpol.2013.08.027 24274510
    [Google Scholar]
  152. Sakane T. Akizuki M. Yoshida M. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J. Pharm. Pharmacol. 1991 43 6 449 451 10.1111/j.2042‑7158.1991.tb03510.x 1681064
    [Google Scholar]
  153. Chou K.J. Donovan M.D. Distribution of antihistamines into the CSF following intranasal delivery. Biopharm. Drug Dispos. 1997 18 4 335 346 10.1002/(SICI)1099‑081X(199705)18:4<335:AID‑BDD22>3.0.CO;2‑W 9158881
    [Google Scholar]
  154. Sherry Chow H-H. Chen Z. Matsuura G.T. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 1999 88 8 754 758 10.1021/js9900295 10430537
    [Google Scholar]
  155. Yajima T. Juni, Saneyoshi M, Hasegawa T, Kawaguchi T. Direct transport of 23-didehydro-3-deoxythymidine (D4T) and its ester derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats. Biol. Pharm. Bull. 1998 21 3 272 277 10.1248/bpb.21.272 9556159
    [Google Scholar]
  156. Wang Y Aun R Tse FLS Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 1998 19 9 571 5 10.1002/(SICI)1099‑081X(199812)19:9<571::AID‑BDD142>3.0.CO;2‑O 9872338
    [Google Scholar]
  157. Dahlin M. Bergman U. Jansson B. Björk E. Brittebo E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm. Res. 2000 17 6 737 742 10.1023/A:1007542618378 10955850
    [Google Scholar]
  158. Schipper N.G.M. Hermens W.A.J.J. Romeyn S.G. Verhoef J. Merkus F.W.H.M. Nasal absorption of 17-beta-estradiol and progesterone from a dimethyl-cyclodextrin inclusion formulation in rats. Int. J. Pharm. 1990 64 1 61 66 10.1016/0378‑5173(90)90179‑8
    [Google Scholar]
  159. Zhao Y.Z. Li X. Lu C.T. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine 2014 10 4 755 764 10.1016/j.nano.2013.10.009 24200526
    [Google Scholar]
  160. Lui C.Y. Amidon G.L. Goldberg A. Intranasal absorption of flurazepam, midazolam, and triazolam in dogs. J. Pharm. Sci. 1991 80 12 1125 1129 10.1002/jps.2600801207 1815070
    [Google Scholar]
  161. Henriksson J. Tjälve H. Uptake of inorganic mercury in the olfactory bulbs via olfactory pathways in rats. Environ. Res. 1998 77 2 130 140 10.1006/enrs.1997.3817 9600806
    [Google Scholar]
  162. Thorne R.G. Hanson L.R. Ross T.M. Tung D. Frey W.H. Delivery of interferon- to the monkey nervous system following intranasal administration. Neuroscience 2008 152 3 785 797 10.1016/j.neuroscience.2008.01.013 18304744
    [Google Scholar]
  163. Alam T. Pandit J. Vohora D. Aqil M. Ali A. Sultana Y. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin. Drug Deliv. 2015 12 2 181 194 10.1517/17425247.2014.945416 25164097
    [Google Scholar]
  164. Kim T.K. Kang W. Chun I.K. Oh S.Y. Lee Y.H. Gwak H.S. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. Eur. J. Pharm. Sci. 2009 38 5 525 532 10.1016/j.ejps.2009.09.019 19804823
    [Google Scholar]
  165. Brenneman K.A. Wong B.A. Buccellato M.A. Costa E.R. Gross E.A. Dorman D.C. Direct olfactory transport of inhaled manganese ((54)MnCl(2)) to the rat brain: Toxicokinetic investigations in a unilateral nasal occlusion model. Toxicol. Appl. Pharmacol. 2000 169 3 238 248 10.1006/taap.2000.9073 11133346
    [Google Scholar]
  166. Aloe L. Bianchi P. De Bellis A. Soligo M. Rocco M. Intranasal nerve growth factor bypasses the blood-brain barrier and affects spinal cord neurons in spinal cord injury. Neural Regen. Res. 2014 9 10 1025 1030 10.4103/1673‑5374.133161 25206755
    [Google Scholar]
  167. Dal Monte O. Noble P.L. Turchi J. Cummins A. Averbeck B.B. CSF and blood oxytocin concentration changes following intranasal delivery in macaque. PLoS One 2014 9 8 103677 10.1371/journal.pone.0103677 25133536
    [Google Scholar]
  168. Harmon B.T. Aly A.E. Padegimas L. Sesenoglu-Laird O. Cooper M.J. Waszczak B.L. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. Gene Ther. 2014 21 5 514 521 10.1038/gt.2014.28 24670994
    [Google Scholar]
  169. Ducharme N. Banks W.A. Morley J.E. Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur. J. Pharmacol. 2010 641 2-3 128 134 10.1016/j.ejphar.2010.05.033 20570588
    [Google Scholar]
  170. Colombo G. Lorenzini L. Zironi E. Brain distribution of ribavirin after intranasal administration. Antiviral Res. 2011 92 3 408 414 10.1016/j.antiviral.2011.09.012 22001322
    [Google Scholar]
  171. Hashizume R. Ozawa T. Gryaznov S.M. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro-oncol. 2008 10 2 112 120 10.1215/15228517‑2007‑052 18287341
    [Google Scholar]
  172. Ma Y.P. Ma M.M. Ge S. Intranasally delivered TGF-1 enters brain and regulates gene expressions of its receptors in rats. Brain Res. Bull. 2007 74 4 271 277 10.1016/j.brainresbull.2007.06.021 17720549
    [Google Scholar]
  173. Thorne R.G. Emory C.R. Ala T.A. Frey W.H. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995 692 1-2 278 282 10.1016/0006‑8993(95)00637‑6 8548316
    [Google Scholar]
  174. Pietrowsky R. Strüben C. Mölle M. Fehm H.L. Born J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: Evidence for a direct nose-brain pathway for peptide effects in humans. Biol. Psychiatry 1996 39 5 332 340 10.1016/0006‑3223(95)00180‑8 8704064
    [Google Scholar]
  175. Pietrowsky R. Thiemann A. Kern W. Fehm H.L. Born J. A nose-brain pathway for psychotropic peptides: Evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology 1996 21 6 559 572 10.1016/S0306‑4530(96)00012‑1 8983091
    [Google Scholar]
  176. Derad I. Willeke K. Pietrowsky R. Born J. Fehm H. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. Am. J. Hypertens. 1998 11 8 971 977 10.1016/S0895‑7061(98)00095‑8 9715790
    [Google Scholar]
  177. Smolnik R. Mölle M. Fehm H.L. Born J. Brain potentials and attention after acute and subchronic intranasal administration ofACTH 4-10 and desacetyl--MSH in humans. Neuroendocrinology 1999 70 1 63 72 10.1159/000054460 10420094
    [Google Scholar]
  178. Kern W. Born J. Schreiber H. Fehm H.L. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 1999 48 3 557 563 10.2337/diabetes.48.3.557 10078556
    [Google Scholar]
  179. Aoki F.Y. Crowley J.C. Distribution and removal of human serum albumintechnetium 99m instilled intranasally. Br. J. Clin. Pharmacol. 1976 3 5 869 878 10.1111/j.1365‑2125.1976.tb00640.x 973982
    [Google Scholar]
  180. Apuhan T. Kocoglu H. Gulcu N. Comparison of lidocaine and levobupivacaine in transnasal fiberoptic laryngoscopy. Am. J. Rhinol. Allergy 2012 26 3 104 106 10.2500/ajra.2012.26.3757 22643937
    [Google Scholar]
  181. Born J. Lange T. Kern W. McGregor G.P. Bickel U. Fehm H.L. Sniffing neuropeptides: A transnasal approach to the human brain. Nat. Neurosci. 2002 5 6 514 516 10.1038/nn0602‑849 11992114
    [Google Scholar]
  182. da Fonseca C.O. Schwartsmann G. Fischer J. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg. Neurol. 2008 70 3 259 266 10.1016/j.surneu.2007.07.040 18295834
    [Google Scholar]
  183. Jones N. Rog D. Olfaction: A review. J. Laryngol. Otol. 1998 112 1 11 24 10.1017/S0022215100139829 9538440
    [Google Scholar]
  184. Dhuria S.V. Hanson L.R. Frey W.H. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J. Pharm. Sci. 2010 99 4 1654 1673 10.1002/jps.21924 19877171
    [Google Scholar]
  185. Roth Y. Chapnik J.S. Cole P. Feasibility of aerosol vaccination in humans. Ann. Otol. Rhinol. Laryngol. 2003 112 3 264 270 10.1177/000348940311200313 12656420
    [Google Scholar]
  186. Bråve A. Hallengärd D. Schröder U. Blomberg P. Wahren B. Hinkula J. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine 2008 26 40 5075 5078 10.1016/j.vaccine.2008.03.066 18450334
    [Google Scholar]
  187. Carp T-N. Metoudi M. Ojha V. Infection-simulator, immunostimulatory and immunomodulatory effects of interferons i and iii in biological systems: A new era in vaccinology and therapeutics possible? Preprints 2024 2022120155 10.20944/preprints202212.0155.v6
    [Google Scholar]
  188. Kozak M. Hu J. The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development. Vaccines 2023 11 3 695 10.3390/vaccines11030695 36992279
    [Google Scholar]
  189. Xie Y. Tian X. Zhang X. Yao H. Wu N. Immune interference in effectiveness of influenza and COVID-19 vaccination. Front. Immunol. 2023 14 1167214 10.3389/fimmu.2023.1167214 37153582
    [Google Scholar]
  190. Illum L. Nasal drug delivery — Recent developments and future prospects. J. Control. Release 2012 161 2 254 263 10.1016/j.jconrel.2012.01.024 22300620
    [Google Scholar]
  191. Vujanic A. Sutton P. Snibson K.J. Yen H.H. Scheerlinck J.P.Y. Mucosal vaccination: Lung versus nose. Vet. Immunol. Immunopathol. 2012 148 1-2 172 177 10.1016/j.vetimm.2011.03.004 21492942
    [Google Scholar]
  192. Wang S. Chen P. Zhang L. Yang C. Zhai G. Formulation and evaluation of microemulsion-based in situ ion-sensitive gelling systems for intranasal administration of curcumin. J. Drug Target. 2012 20 10 831 840 10.3109/1061186X.2012.719230 22934854
    [Google Scholar]
  193. Wang S.H. Fan Y. Makidon P.E. Cao Z. Baker J.R. Induction of immune tolerance in mice with a novel mucosal nanoemulsion adjuvant and self-antigen. Nanomedicine 2012 7 6 867 876 10.2217/nnm.11.187 22420425
    [Google Scholar]
  194. Neutra M.R. M cells in antigen sampling in mucosal tissues. Curr. Top. Microbiol. Immunol. 1999 236 17 32 10.1007/978‑3‑642‑59951‑4_2
    [Google Scholar]
  195. Debertin A.S. Tschernig T. Tönjes H. Kleemann W.J. Tröger H.D. Pabst R. Nasal-associated lymphoid tissue (NALT): Frequency and localization in young children. Clin. Exp. Immunol. 2003 134 3 503 507 10.1111/j.1365‑2249.2003.02311.x 14632758
    [Google Scholar]
  196. Debertin A.S. Tschernig T. Schürmann A. Bajanowski T. Brinkmann B. Pabst R. Coincidence of different structures of mucosa-associated lymphoid tissue (MALT) in the respiratory tract of children: No indications for enhanced mucosal immunostimulation in sudden infant death syndrome (SIDS). Clin. Exp. Immunol. 2006 146 1 54 59 10.1111/j.1365‑2249.2006.03190.x 16968398
    [Google Scholar]
  197. Goeringer G.C. Vidi B. The embryogenesis and anatomy of Waldeyer’s ring. Otolaryngol. Clin. North Am. 1987 20 2 207 217 10.1016/S0030‑6665(20)31638‑8 3601384
    [Google Scholar]
  198. Fortuna A. Schindowski K. Sonvico F. Editorial: Intranasal drug delivery: Challenges and opportunities. Front. Pharmacol. 2022 13 868986 10.3389/fphar.2022.868986 35308245
    [Google Scholar]
  199. Penovich P Wheless JW Hogan RE Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: Results from an exit survey of a phase 3, open-label, repeat-dose safety study. Epilepsy Behav 2021 121 Pt A 108013 10.1016/j.yebeh.2021.108013 34022621
    [Google Scholar]
  200. Nunley S. Glynn P. Rust S. Vidaurre J. Albert D.V.F. Patel A.D. A hospital-based study on caregiver preferences on acute seizure rescue medications in pediatric patients with epilepsy: Intranasal midazolam versus rectal diazepam. Epilepsy Behav. 2019 92 53 56 10.1016/j.yebeh.2018.12.007 30611934
    [Google Scholar]
  201. Kapoor M. Cloyd J.C. Siegel R.A. A review of intranasal formulations for the treatment of seizure emergencies. J. Control. Release 2016 237 147 159 10.1016/j.jconrel.2016.07.001 27397490
    [Google Scholar]
  202. Rajpoot K. Jain S.K. Irinotecan hydrochloride trihydrate loaded folic acid-tailored solid lipid nanoparticles for targeting colorectal cancer: Development, characterization, and in vitro cytotoxicity study using HT-29 cells. J. Microencapsul. 2019 36 7 659 676 10.1080/02652048.2019.1665723 31495238
    [Google Scholar]
  203. Rajpoot K. Jain S.K. 99mTc-labelled and pH-awakened microbeads entrapping surface-modified lipid nanoparticles for the augmented effect of oxaliplatin in the therapy of colorectal cancer. J. Microencapsul. 2020 37 8 609 623 10.1080/02652048.2020.1829141 32985297
    [Google Scholar]
  204. Rajpoot K. Jain S.K. The role of nanoparticles in the treatment of gastric cancer Nano Drug Delivery Strategies for the Treatment of Cancers. Amsterdam, Netherlands Elsevier 2021 165 189
    [Google Scholar]
  205. Das S. Kaur S. Rai V.K. Gastro-retentive drug delivery systems: A recent update on clinical pertinence and drug delivery. Drug Deliv. Transl. Res. 2021 11 5 1849 1877 10.1007/s13346‑020‑00875‑5 33403646
    [Google Scholar]
  206. Shukla A.K. Singh S.K. Goel M.K. Garg A. Rajpoot K. Jain S.K. Multifunctional nanocarrier-mediated approaches and conventional therapies for effective treatment of cancer Multifunctional Nanocomposites for Targeted Drug Delivery in Cancer Therapy. Amsterdam, Netherlands Elsevier 2024 35 61 10.1016/B978‑0‑323‑95303‑0.00005‑8
    [Google Scholar]
  207. Kumar A. Pandey A.N. Jain S.K. Nasal-nanotechnology: Revolution for efficient therapeutics delivery. Drug Deliv. 2016 23 3 671 683 10.3109/10717544.2014.920431 24901207
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128392902250916114510
Loading
Intranasal Drug Delivery: Exploiting Nasal Anatomy for Enhanced Therapeutic Outcomes
Bentham Science Publishers ; https://doi.org/10.2174/0113816128392902250916114510
/content/journals/cpd/10.2174/0113816128392902250916114510
/content/journals/cpd/10.2174/0113816128392902250916114510
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Nanotechnology ; nose-to-brain delivery ; intranasal route ; therapeutic outcomes ; blood-brain barrier ; targeted drug delivery

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test